AstraZeneca Halts Late-Stage Lung Cancer Drug Trial
Experimental treatment failed to meet survival goals in Phase III study

AstraZeneca announced on August 17 that it is ending its Phase III eVOLVE-Lung02 clinical trial after an independent monitoring committee concluded the experimental immunotherapy volrustomig was unlikely to achieve its primary survival goals. The study compared the treatment, used alongside chemotherapy, with Merck's Keytruda plus chemotherapy in patients with advanced non-small cell lung cancer, the most common form of the disease.
The company said the decision was based on the treatment's lack of expected effectiveness rather than new safety concerns. AstraZeneca reported that no new safety signals were identified during the interim review and said the results would help guide future oncology research. Company officials described the outcome as disappointing but emphasized that other late-stage studies of volrustomig for different cancers will continue.
The setback comes as AstraZeneca works toward ambitious long-term growth targets and expands its cancer drug portfolio. Analysts said the decision highlights the difficulty of improving on established first-line lung cancer treatments, where Keytruda remains one of the leading therapies worldwide.
While the lung cancer program has ended, AstraZeneca said Phase III trials of volrustomig in cervical cancer, malignant pleural mesothelioma, and head and neck cancer remain on schedule. Future results from those studies will help determine whether the experimental drug can still play a role in the company's oncology strategy.